Advances in the treatment of hepatitis B;Avanços no tratamento da hepatite pelo vírus B

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 40, Issue 4, 2007, Pages 451-462

  Ferreira, Marcelo Simão ^a,b   Borges, Aércio Sebastião ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b NONE   (Brazil)

Author keywords

Hepatitis B; Hepatocellular arcinoma; Interferon ; Liver cirrhosis; Nucleoside nucleotide analogues

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; REVIEW; TREATMENT OUTCOME; VIRUS REPLICATION; VIRUS RESISTANCE;

HEPATITIS B VIRUS;

EID: 34548595209     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822007000400016     Document Type: Review

References (64)

1. Benhamou, Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. Journal of Hepatology 44:90-94, 2006.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 42:1208-1236, 2005.
3. Buti M, Cotrina M, Jardi R. Two years of lamivudine therapy in anti-Hbe positive patients with chronic hepatitis B. Journal of Viral Hepatitis 11:432-438, 2004.
4. Chan HLY, Lai CL, Cho M, Heathcote J. A randomized trial of telbivudine (LDT) vs adefovir for HbeAg positive chronic hepatitis B results of the primary week 24 analysis. Journal of Hepatology 44:524-525, 2006.
5. Chang T, Gish R, Deman R. A comparison of entecavir and lamivudine for HbeAg-positive chronic hepatitis B. The New England Journal of Medicine 354:1001-1010, 2006.
6. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER; BEHOLD Study Group. A dose ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B. Gastroenterology 129:1198-1209, 2005.
7. Chu CJ, Hussain M, Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 36:1408-1415, 2002.
8. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology 35:1274-1276, 2002.
9. Cinjeevaran HS, Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology 34:204-206, 2001.
10. Chung YH, Lee KS, Kim JH, Ryn SH, Paik SW. One year treatment with clevudine demonstrated significant viral suppression and biochemical improvement in chronic hepatitis B. Journal of Hepatology 44:524-525, 2006.
11. Colin JF, Cazals-Hatem D, Loriot MA. Influence of human immunodeficiency virus infection on chronic hepatitis B in homossexual men. Hepatology 29: 1306-1310, 1999.
12. th Conference on Retroviruses and Opportunistic Infections; 2006; Denver, Colorado, USA.
13. Colonno RJ, Rose R, Baldick CJ, Levine S,Yu CF, Walsh A, Fang J, Hsu M, Mazzuco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 44:1656-1665, 2006.
14. Dando TM, Plosker GL. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 63:2215-2234, 2003.
15. Den Brinker M, Wit FW, Wertheim-van Dillen PM. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14: 2895-2902, 2000.
16. Dienstag JL, Ciancara J, Karayalcin S. Durability of serologic response after lamivudine treatment of chronic hepatitis. B. Hepatology 37:748-755, 2003.
17. Di Martino V, Thevenot T, Colin JF. Influence of HIV infection on the response to interferon therapy and the long-tern outcome of chronic hepatitis B. Gastroenterology 123:1812-1822, 2002.
18. Dore GJ, Cooper DA, Barrett C. Dual efficacy of lamivudine treatment HIV-hepatitis B coinfected persons in a randomized, controlled study (CAESAR). Journal of Infections Diseases 180:607-613, 1999.
19. Ferreira MS. Diagnóstico e tratamento da hepatite B. Revista da Sociedade Brasileira de Medicina Tropical 33:389-400, 2000.
20. Fontana RJ. Management of patients with decompensated HBV cirrhosis. Seminars in Liver Diseases 23:89-100, 2003.
21. Fung SK, Lok ASF. Management of patients with hepatitis B virus-induced cirrhosis. Journal of Hepatology 42:54-64, 2005.
22. Ganem D, Prince AM. Hepatitis B vírus infection - natural history and clinical consequences. The New England Journal of Medicine 350:1118-1129, 2004.
23. Ghany M, Lutchman G, Kleiner D. Lamivudine and adefovir versus adefovir alone for HbeAg-positive chronic hepatitis B. Hepatology 42:591-592, 2005.
24. Guan R, Lai CL, Liaw YF. Efficacy and safety of 5 years lamivudine treatment of chinese patients with chronic hepatitis B. Journal Gastroenterology and Hepatology 16:A60-A61, 2001.
25. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ. Long-term therapy with adefovir dipivoxil for HbeAg-negative chronic hepatitis B. The New England Journal of Medicine 352:2673-2681, 2005.
26. Hayashi PH, DiBisceglie AM. The progression of hepatitis B and C infections to chronic liver diseases and hepatocelular carcinoma: presentation, diagnosis, screening, prevention and treatment of hepatocellular carcinoma. Infections Disease Clinics of North América 20:1-25, 2006.
27. Hoff J, Bani-Sadr F, Gassin M, Faffi F. Evaluation of chronic hepatitis B virus infection in co-infected patients receiving lamivudine as component of anti-HIV regimen. Clinical Infections Diseases 32:963-969, 2001.
28. Hoofnagle JH. Hepatitis B - preventable and now treatable. The New England Journal of Medicine 345:1074-1076, 2006.
29. Hsu YS, Chren RN, Yeh CT. Long-term outcome after spontaneous HbeAg seroconversion in patients with chronic hepatitis B. Hepatology 35:1522-1527, 2002.
30. Janssen HL, Van Zonnveld M, Senturk H. Pegylated interferon alfa-2a alone or in combination with lamivudine for HbeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123-129, 2005.
31. Keefe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright T. A treatment algorithm for the management of chronic hepatitis B vírus infection in the United States: na update. Clinical Gastroenterology and Hepatology 2006 4:1-27, 2006.
32. Lacombe K, Gozian J, Boelle PY. Long-term hepatitis B virus dynamics in HIV- HIV-hepatitis B virus-co-infected patients with tenofovir disoproxil fumarate. AIDS 19:907-915, 2005.
33. Lan GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Berg T, for the Peginterferon alfa-2a HbeAg positive chronic hepatitis B study group. Peginterferon alfa-2a, Lamivudine, and the combination for HbeAg-positive chronic Hepatitis B. The New England Journal of Medicine 352:2682-2695, 2005.
34. Leung N, Gish RG, Wang C. A randomised double blind comparison of 3 doses of emtricitabine in patients with chronic hepatitis B given 48 weeks of treatment. Hepatology 34:349A.
35. Liaw YF, Leving N, Guan R. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver International 25:472-489, 2005.
36. Liaw YF, Sung JJY, Chow WC. Lamivudine for patients with chronic hepatitis B and advanced liver disease. The New England Journal of Medicine 351:1521-1531, 2004.
37. LLoeje VH, Yang HI, Su J. Predicting cirrosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678-686, 2006.
38. Locarnini S, Hatzakis A, Heathcote J. Management of antiviral resistance in patients with chronic hepatitis B. Antiviral Therapy 9:679-693, 2004.
39. Lok AS, McMahon B. Chronic hepatitis B: update of recommendations. Hepatology 39:857-861, 2004.
40. Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. Journal of Viral Hepatitis 12:333-345, 2005.
41. Marcellin P, Chan TT, Lin SG, Tong MJ, Stievert W, Shiffman ML, Jeffers L, for the Adefovir Dipivoxil 437 study group: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. The New England Journal of Medicine 348:808-816, 2003.
42. Marcellin P, Lan GKK, Bonino F, Farci P, Hadziyannis S, Jin R. For the Peginterferon Alfa-2a HbeAg-negative chronic hepatitis B study group. The New England Journal of Medicine 351:1206-1217, 2004.
43. Marcellin P, Mommeja-Marin H, Sacks SL. A phase II dose escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40:140-148, 2004.
44. Matthews GV, Bartholomeusz A, Locarnini S. Characteristics of drug resistant HBV in an international collaborative study of HIV/HBV coinfected individuals on extended lamivudine therapy. AIDS 20:863-870, 2006.
45. Nunez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in human immunodeficiency virus-infected patients: present and future. Clinical Infections Diseases 37: 1678-1685, 2003.
46. Perrilo R, Hann HW, Mutiner D. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126:81-90, 2004.
47. th Conference on Retroviruses and Opportunistic Infection (Boston). Foundation for Retrovirology and Human Health, Alexandria, VA 2005.
48. th Abstract of Conference on Retroviruses and Opportunistic infections. Boston, MA, USA, p.124, 2005.
49. Puoti M, Spinetti A, Ghezzi A. Mortality for liver disease in patients with HIV infection: a cohort study. Journal of Acquired Immunodeficiency Syndrome 24: 211-217, 2000.
50. Realdi G, Fattovich G, Hadziyannis S. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. Journal of Hepatology 21:656-666, 1994.
51. Rector WG, Govindarajan S, Horsburgh CR. Hepatic inflammation, hepatitis B replication, and cellular immune function in homossexual males with chronic hepatitis B and antibody to human immunodeficiency virus. American Journal of Gatroenterology 83:262-266, 1988.
52. Salmon-Ceron D, Lewden C, Morlat P. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. Journal of Hepatology 42:799-805, 2005.
53. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. Journal of Hepatology 44:593-606, 2006.
54. Sheldon JA, Camino N, Rodes B. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antiviral Therapy 10:727-734, 2005.
55. Sheldon JA, Corral A, Rodes B. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir dipivoxil monotherapy. Hepatology 43:1385-1391, 2006.
56. Sherman M, Yurdaydin C, Soliano J. Entecavir for treatment of lamivuine-refratory, HBeAg-positive chronic hepatitis B. Gatroenterology 130:2039-2049, 2006.
57. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J. Entecavir for the treatment of lamivudine-refractory, HbeAg-positive chronic hepatitis B. Gastroenterology 130:2039-2049, 2006.
58. Simpson ND, Simpson PW, Ahmed AM. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. Journal of Clinical Gastroenterology 37:68-71, 2003.
59. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C ou B virus infection. JAMA 283: 74-80, 2000.
60. Thio CL, Seaberg EC, Skolasky Jr R. HIV-1, hepatitis B virus and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1936, 2002.
61. Thomas DL, Cannon RO, Shapiro CN. Hepatitis C, hepatitis B and human immunodeficiency virus infections among non-intravenous drug using patients attending clinics for sexually transmitted diseases. Journal of Infections Diseases 169:990-995, 1994.
62. Webster GJ, Reignat S, Maini MK. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32: 1117-1124, 2000.
63. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ, for the Taiwan Community-based cancer screening project group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. The New England Journal of Medicine 347:168-174, 2002.
64. Zoulim F. Assessment of treatment efficacy in HBV infection and disease. Journal of Hepatology 44:95-99, 2006.